Italia markets closed

Molecular Partners AG (0QXX.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
3,3750+0,1150 (+3,53%)
Alla chiusura: 03:53PM BST
Schermo intero
Chiusura precedente3,2600
Aperto0,0000
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume12.410
Media Volume6.578
Capitalizzazione604.661
Beta (mensile su 5 anni)0,80
Rapporto PE (ttm)0,01
EPS (ttm)3,3100
Prossima data utili15 mar 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

    New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad range of tumor targets RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors and for expansion of targets amenable to radiotherapy ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDA

  • GlobeNewswire

    Molecular Partners Reports H1 2023 Corporate Highlights and Financials

    Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing reg

  • GlobeNewswire

    Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

    RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will